HC Wainwright & Co. Initiates Coverage On Soleno Therapeutics with Buy Rating, Announces Price Target of $70
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Soleno Therapeutics with a Buy rating and set a price target of $70.
September 03, 2024 | 11:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Soleno Therapeutics with a Buy rating and a price target of $70, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a high price target suggests confidence in Soleno Therapeutics' future performance, likely leading to positive investor sentiment and potential stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100